NCT03498222 - Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin | Biotech Hunter

Timeline

Start Date

June 1, 2018

Primary Completion Date

January 31, 2020

Study Completion Date

December 31, 2021

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Atezolizumab

Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).

DRUG

Pemetrexed

Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.

DRUG

Carboplatin

Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.

DRUG

ADI PEG20

Administered by intramuscular (IM) injection to patients once weekly.